|
[1] Chinese Society of Hepatology and Chinese Society of Infec-tious Diseases, Chinese Medical Association. The guideline ofprevention and treatment for chronic hepatitis B:A 2015 up-date[J]. J Clin Hepatol, 2015, 31 (12) :1941-1960. (inChinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
|
|
[2] WONG GL, SETO WK, WONG VW, et al. Review article:Long-term safety of oral anti-viral treatment for chronic hep-atitis B[J]. Aliment Pharmacol Ther, 2018, 47 (6) :730-737.
|
|
[3] FUNG J, SETO WK, LAI CL, et al. Extrahepatic effects of nu-cleoside and nucleotide analogues in chronic hepatitis B treat-ment[J]. J Gastroenterol Hepatol, 2014, 29 (3) :428-434.
|
|
[4] WONG GL, TSE YK, WONG VW, et al. Long-term safety oforal nucleos (t) ide analogs for patients with chronic hepatitisB:A cohort study of 53, 500 subjects[J]. Hepatology, 2015, 62 (3) :684-693.
|
|
[5] LIAW YF, GANE E, LEUNQ N, et al. 2-Year GLOBE trial results:Telbivudine is superior to lamivudine in patients with chronic hep-atitis B[J]. Gastroenterology, 2009, 136 (2) :486-495.
|
|
[6] MATTHEWS SJ. Telbivudine for the management of chronic hepa-titis B virus infection[J]. Clin Ther, 2007, 29 (12) :2635-2653.
|
|
[7] GANE EJ, WANG Y, LIAW YF, et al. Efficacy and safety ofprolonged 3-year telbivudine treatment in patients with chron-ic hepatitis B[J]. Liver Int, 2011, 31 (5) :676-684.
|
|
[8] ZOU XJ, JIANG XQ, TIAN DY. Clinical features and risk fac-tors of creatine kinase elevations and myopathy associatedwith telbivudine[J]. J Viral Hepat, 2011, 18 (12) :892-896.
|
|
[9] CHEN L, CHENG C, CHEN B, et al. Cumulative incidenceand risk factors of creatine kinase elevation associated withtelbivudine[J]. Eur J Clin Pharmacol, 2016, 72 (2) :235-241.
|
|
[10] REN JB, WANG Y, LI HY, et al. Telbivudine-associated cre-atine kinase elevation in chronic hepatitis B patients[J]. ChinJ Hepatol, 2012, 20 (9) :641-643. (in Chinese) 任江波, 王宇, 李红艺, 等.替比夫定治疗慢性乙型肝炎期间肌酸激酶升高的观察与分析[J].中华肝脏病杂志, 2012, 20 (9) :641-643.
|
|
[11] LIN G, WU Y, LI X, et al. The effect on creatine phosphoki-nase of the patients with chronic hepatitis B were treated withtelbivudine, entecavir, adefovir dipivoxil and lamivudine[J].Hepatology, 2011, 54:1044A.
|
|
[12] BUT DY, YUEN MF, FUNG J, et al. Safety evaluation of telbi-vudine[J]. Expert Opin Drug Saf, 2010, 9 (5) :821-829.
|
|
[13] FLEISCHER RD, LOK AS. Myopathy and neuropathy associat-ed with nucleos (t) ide analog therapy for hepatitis B[J]. JHepatol, 2009, 4:787-791.
|
|
[14] FINSTERER J, AY L. Myotoxicity of telbivudine in pre-exist-ing muscle damage[J]. Virol J, 2010, 7:323-323.
|
|
[15] FONTANA RJ. Side effects of long-term oral antiviral therapyfor hepatitis B[J]. Hepatology, 2009, 49 (Suppl 5) :s185-s195.
|
|
[16] LANGE CM, BOJUNGA J, HOFMANN WP, et al. Severe lac-tic acidosis during treatment of chronic hepatitis B with ente-cavir in patients with impaired liver function[J]. Hepatology, 2009, 50 (6) :2001-2006.
|
|
[17] SINGAL AK, FONTANA RJ. Meta-analysis:Oral anti-viralagents in adults with decompensated hepatitis B virus cirrhosis[J]. Aliment Pharmacol Ther, 2012, 35 (6) :674-689.
|
|
[18] SAITOH A, HAAS RH, NAVIAUX RK, et al. Impact of nucleo-side reverse transcriptase inhibitors on mitochondrial DNA andRNA in human skeletal muscle cells[J]. Antimicrob AgentsChemother, 2008, 52 (8) :2825-2830.
|
|
[19] KOCZOR CA, LEWIS W. Nucleoside reverse transcriptase in-hibitor toxicity and mitochondrial DNA[J]. Expert Opin DrugMetab Toxicol, 2010, 6 (12) :1493-1504.
|
|
[20] XU H, WANG Z, ZHENG L, et al. Lamivudine/telbivudine-associated neuromyopathy:neurogenic damage, mitochondri-al dysfunction and mitochondrial DNA depletion[J]. J ClinPathol, 2014, 67 (11) :999-1005.
|
|
[21] LEE JM, SHIN JH, PARK YE, et al. Mitochondrial myopathiescaused by prolonged use of telbivudine[J]. Ann Clin Neuro-physiol, 2017, 19 (1) :40-45.
|
|
[22] AMBANG T, TAN JS, ONG S, et al. Clinicopathological fea-tures of telbivudine-associated myopathy[J]. PLo S One, 2016, 11 (9) :e0162760.
|
|
[23] YUAN K, GUOCHUN W, HUANG Z, et al. Entecavir-associ-ated myopathy:A case report and literature review[J]. Mus-cle Nerve, 2014, 49 (4) :610-614.
|
|
[24] WANG M, DA Y, CAI H, et al. Telbivudine myopathy in a pa-tient with chronic hepatitis B[J]. Int J Clin Pharm, 2012, 34 (3) :422-425.
|
|
[25] HERNANDEZ-LAIN A, GUERRERO AM, DOMINGUEZ-GONZALEZ C, et al. A novel RRM2B gene variant associat-ed with Telbivudine-induced mitochondrial myopathy[J]. JNeurol Sci, 2015, 358 (1-2) :481-483.
|
|
[26] YAMANAKA H, GATANAGA H, KOSALARAKSA P, et al. No-vel mutation of human DNA polymerase gamma associatedwith mitochondrial toxicity induced by anti-HIV treatment[J].J Infect Dis, 2007, 195 (10) :1419-1425.
|
|
[27] ZHENG RJ, ZHANG LJ, ZHANG YX, et al. A preliminary stud-y on the mechanism of nucleoside analogues induced creatinekinase increasement in chronic hepatitis B patients[J]. J ClinExp Med, 2017, 16 (9) :856-859. (in Chinese) 郑嵘炅, 张丽娟, 张跃新, 等.核苷类似物致慢性乙型肝炎患者肌酸激酶增高的机制的初步研究[J].临床和实验医学杂志, 2017, 16 (9) :856-859.
|
|
[28] JIANFEI L, MIN W, CHUNLAI M, et al. The Ca (2+) /Ca MKK2axis mediates the telbivudine induced upregulation of creatine ki-nase:Implications for mechanism of antiviral nucleoside analogs'side effect[J]. Biochem Pharmacol, 2017, 146:224-232.
|
|
[29] LIU YF, XIONG HF, LIU JY, et al. One case of entecavir-in-duced rhabdomyolysis in a patient with chronic hepatitis B[J/CD]. Chin J Liver Dis:Electronic Edition, 2017, 9 (1) :91-93. (in Chinese) 刘玉凤, 熊号峰, 刘景院, 等.恩替卡韦治疗慢性乙型肝炎患者导致横纹肌溶解1例[J/CD].中国肝脏病杂志:电子版, 2017, 9 (1) :91-93.
|
|
[30] JIN JL, HU P, LU JH, et al. Lactic acidosis during telbivudinetreatment for HBV:A case report and literature review[J].World J Gastroenterol, 2013, 19 (33) :5575-5580.
|
|
[31] MENG YJ, YANG GP. Association of nucleos (t) ide analogueswith mitochondrial myopathy-related adverse events[J].Central South Pharm, 2011, 9 (10) :779-783. (in Chinese) 孟亚军, 阳国平.核苷 (酸) 类似物与线粒体肌病相关的不良反应研究[J].中南药学, 2011, 9 (10) :779-783.
|
|
[32] LEE SW, JANG JH, KIM BJ. Dysphagia could be the firstpresenting symptom of telbivudine-induced myopathy[J].Int Med J, 2013, 43 (9) :1048-1049.
|
|
[33] ZHANG XS, JIN R, ZHANG SB, et al. Clinical features of ad-verse reactions associated with telbivudine[J]. World J Gas-troenterol, 2008, 14 (22) :3549-3553.
|
|
[34] WU RT, LI GM. Effect of telbivudine on blood creatine kinasein patients with chronic hepatitis B[J]. Jilin Med J, 2016, 37 (2) :398-399. (in Chinese) 吴汝桐, 李桂媚.替比夫定对慢性乙型肝炎患者血肌酸激酶的影响及分析[J].吉林医学, 2016, 37 (2) :398-399.
|
|
[35] TSAI WL, SUN WC, CHENG JS. Chronic hepatitis B with sponta-neous severe acute exacerbation[J]. Int J Mol Sci, 2015, 16 (12) :28126-28145.
|
|
[36] HU QQ, SHI LL, TAN CB, et al. Mitochondrial toxicity mecha-nism of nucleoside analogues and its clinical manifestations[J]. Chin J Pharmacol Toxicol, 2013, 27 (5) :885-888. (inChinese) 胡倩倩, 时丽丽, 谭初兵, 等.核苷类似物线粒体毒性机制及临床表现[J].中国药理学与毒理学杂志, 2013, 27 (5) :885-888.
|
|
[37] Experts Committee of Management of Side Effects of Nucleos (t) ide Analogues for Hepatitis B Virus. Consensus on man-agement of side effects of nucleos (t) ide analogues for hepati-tis B virus[J/CD]. Chin J Liver Dis:Electronic Edition, 2016, 8 (3) :10-14. (in Chinese) 核苷 (酸) 类似物不良反应管理专家委员会.抗乙型肝炎病毒核苷 (酸) 类似物不良反应管理专家共识[J/CD].中国肝脏病杂志:电子版, 2016, 8 (3) :10-14.
|
|
[38] ASSY N, DJIBRE A. Vitamin D supplementprevents myalgiaand elevation of CPK in chronic hepatitis B patients treatedwith telbivudine[J]. J Hepatol, 2011, 54 (11) :s283.
|
|
[39] ROSENFELDT FL, MIJCH A, MCCRYSTAL G, et al. Skeletalmyopathy associated with nucleoside reverse transcriptase in-hibitor therapy:Potential benefit of coenzyme Q10 therapy[J]. Int J STD AIDS, 2005, 16 (12) :827-829.
|
DownLoad: